Biotech News

Gilead Sciences Inc., AT&T Inc. and Amgen Inc. were among the stocks actively trading Tuesday evening, with shares of Gilead climbing after handily beating Wall Street's quarterly earnings and revenue expectations and reporting a sales surge for its new hepatitis C treatment.

Today: Gilead Sciences demolishes earnings expectations thanks to powerful sales of breakthrough hepatitis C drug Sovaldi.

US stocks rose on Tuesday as a host of solid earnings reports, along with strength in the healthcare sector, helped lift the S&P 500 and Nasdaq to their sixth straight advance.

Gilead Sciences is among the big biotech companies that have seen their shares whipsaw in the recent sell-off in biotech stocks .

Amid a relative dearth of economic data and the lack of fresh news in Ukraine, investors are focusing on the latest batch of U.S. corporate earnings and the slew of developments in the pharmaceuticals industry.

A former pharmaceutical executive has been sentenced to 15 months in prison for his role in an insider trading scheme.

The company badly missed Wall Street's expectations for both earnings per share and revenue, sending down its shares.

Thank you, Netflix. The company not only provides programming to fill your down time, it's also helping boost the stock market today.

Drug makers took center stage in European trading Tuesday, with shares of AstraZeneca PLC climbing on news of a potential takeover bid, and GlaxoSmithKline PLC rising as it sells one of its units in a multibillion-dollar deal.

GlaxoSmithKline and Swiss rival Novartis are to create a consumer healthcare powerhouse as part of a string of deals in the pharmaceuticals sector today.

Drug maker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.

Shares in Valeant Pharmaceutical International Inc. soared in after-hours trading in New York on Monday after the Quebec-based company announced it had teamed with activist investor Bill Ackman in what looked to be a US$40-billion bid for Botox maker Allergan.

Activist investor William Ackman teamed up with Canadian drugmaker Valeant Pharmaceuticals International Inc to make a joint run at buying wrinkle-treatment maker Allergan Inc, according to security filings on Monday.

Gado Labbo holds her 5-year-old son, Yusuf, at a clinic in Dareta. In 2010, when Yusuf first entered the clinic, he had a blood lead level 30 times higher than the amount the Centers for Disease Control and Prevention considers dangerous.

Pfizer Inc has agreed to pay $190 million to settle a class action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy drug Neurontin, according to court documents filed on Monday.

Aastrom Biosciences , a developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, reported that it has entered into an agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine business for $6.5 million, with $4 million payable in cash at closing and $2.5 million payable ... (more)

U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.

Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

The future in feeding the projected more than 9 billion world population by 2050 will require doubling the world's food production, according to the most accepted projections.

In a bid to create more productive partnerships with industry, Scripps Research Institute has launched Scripps Advance, a vehicle for turning promising projects from inside and outside Scripps's labs into drug candidates.